Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Cash from Investing Activities: 2014-2024

Historic Cash from Investing Activities for Cidara Therapeutics (CDTX) over the last 11 years, with Dec 2024 value amounting to -$129,000.

  • Cidara Therapeutics' Cash from Investing Activities fell 166381.13% to -$176.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$176.4 million, marking a year-over-year decrease of 40642.26%. This contributed to the annual value of -$129,000 for FY2024, which is 74.46% up from last year.
  • Cidara Therapeutics' Cash from Investing Activities amounted to -$129,000 in FY2024, which was up 74.46% from -$505,000 recorded in FY2023.
  • Over the past 5 years, Cidara Therapeutics' Cash from Investing Activities peaked at -$41,000 during FY2021, and registered a low of -$505,000 during FY2023.
  • Over the past 3 years, Cidara Therapeutics' median Cash from Investing Activities value was -$129,000 (recorded in 2024), while the average stood at -$250,667.
  • As far as peak fluctuations go, Cidara Therapeutics' Cash from Investing Activities tumbled by 431.43% in 2020, and later soared by 77.96% in 2021.
  • Cidara Therapeutics' Cash from Investing Activities (Yearly) stood at -$186,000 in 2020, then surged by 77.96% to -$41,000 in 2021, then slumped by 187.80% to -$118,000 in 2022, then tumbled by 327.97% to -$505,000 in 2023, then spiked by 74.46% to -$129,000 in 2024.